According to Surveyed US Oncologists and Urologists, Patient Share of Sanofi’s Jevtana Has Increased Significantly in Third-Line Metastatic Castrate-Resistant Prostate Cancer Setting Today Compared with Six Months Ago

According to Surveyed US Oncologists and Urologists, Patient Share of Sanofi’s Jevtana Has Increased Significantly in Third-Line Metastatic Castrate-Resistant Prostate Cancer Setting Today Compared with Six Months Ago

Andrew Merron, +44 20 7332 7454orChristopher Comfort, 781-993-2597

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceuticals issues, has released findings from the report, in which 50 urologists and 49 medical oncologists were surveyed about their current and expected treatment practices for prostate cancer.

The study finds that patient share of conventional hormonal therapy alone has significantly fallen from Q1 2012 to Q3 2012 in the second- and third-line metastatic castrate-resistant prostate cancer (MCRPC) settings. However, patient share of Jevtana has significantly increased in the third-line setting over the same time period, and Janssen’s Zytiga patient share has also increased in the second-line setting and now is prescribed to more than a quarter of all second-line metastatic castrate-resistant prostate cancer patients.

“Conventional hormonal therapy alone remains the mainstay of treatment in asymptomatic/minimally symptomatic metastatic castrate-resistant prostate cancer although Dendreon’s Provenge, a personalized immunotherapy, has seen an increase in patient share in this setting,” said BioTrends Oncology Therapeutic Director, Andrew Merron, Ph.D. “It is important to consider however, that there are differences between urologists’ and oncologists’ reporting of patient shares for metastatic castrate-resistant prostate cancer; for example, urologists say that just over a fifth of their second-line MCRPC patients currently receive Zytiga compared with more than a third according to surveyed oncologists.”

The report assesses the burden of care of prostate cancer patients among urologists and oncologists, and finds that urologists are the more likely specialist to treat newly diagnosed prostate cancer and biochemically recurrent patients but oncologists mainly control the treatment of metastatic castrate-resistant prostate cancer.

With respect to important attributes of therapies used to treat MCRPC, surveyed physicians (both urologists and oncologists) consider improving overall survival the most significant attribute when choosing an agent to treat MCRPC, nevertheless, pain palliation is also perceived to be a highly important attribute; conversely, attributes associated with drug sales representatives and patient preference are perceived to be less important. Zytiga and Provenge score well on low incidence of hematological toxicities, but Zytiga scores higher than Provenge with respect to delaying time to progression (which is rated as a more important attribute). Overall, Zytiga is perceived to perform the best out of the profiled therapies on most clinical attributes, including the most highly weighted attributes.

is a bi-annual syndicated report designed to provide a view of the current and future management of prostate cancer based on primary research fielded with 50 urologists and 50 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. We will be publishing a European TreatmentTrends Prostate Cancer study later in October 2012 to gauge urologists’ and medical oncologists’ perspectives of current prostate cancer treatment in the largest European markets (Germany, United Kingdom, France, Spain and Italy). BioTrends is also actively tracking Zytiga and Xtandi (enzalutamide) through our LaunchTrends report offerings.

BioTrends Research Group, LLC provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or .

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.